Today
-0.47%
5 Days
+2.72%
1 Month
-1.14%
6 Months
+12.11%
Year to Date
+10.39%
1 Year
+58.95%
• Novo Nordisk raised full-year sales and operating profit guidance amid strong metabolic drug demand. • Clinical data shows efficacy for cardiovascular and kidney diseases, expanding the potential patient base. • Current technical indicators show a neutral MACD signal and oversold Williams %R conditions.
• Insmed shares rose following positive clinical trial data and potential acquisition interest. • Analysts revised revenue models, setting an average price target of $196.74. • Technical indicators show a sell signal with the stock currently in oversold territory.
• McKesson shares declined following margin contraction in the U.S. Pharmaceutical segment. • Management maintained full-year earnings guidance, disappointing investors seeking an upward revision. • Regulatory scrutiny regarding drug pricing and reimbursement creates significant uncertainty for the firm.
• McKesson reported fiscal first-quarter earnings exceeding consensus expectations across core metrics. • Management raised full-year earnings guidance, citing strength in oncology and biopharma services. • The company leads its industry with $403.43 billion in latest annual revenue.
• Bristol-Myers Squibb lowered its financial outlook due to high costs replacing aging drugs. • Investors are concerned about slow adoption rates for the company's new product launches. • Federal drug pricing negotiations create valuation uncertainty and a price ceiling for shares.
• Amgen shares rose following strong quarterly earnings and increased full-year guidance. • Positive clinical trial updates for the obesity drug MariTide boosted investor confidence. • Analysts raised price targets citing improved margins and robust product portfolio growth.


| Shareholders | Proportion |
|---|---|
| Lilly Endowment, Inc. | 9.76% |
| Vanguard Capital Management, LLC | 5.67% |
| PNC Investments LLC | 5.43% |
| BlackRock Institutional Trust Company, N.A. | 4.44% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 46.65% |
| Investment Advisor/Hedge Fund | 19.18% |
| Foundation | 9.76% |
| Research Firm | 2.14% |
Related Instruments
Popular Instruments